Single-arm, single-center, open-label clinical study for CD19-BCMA chimeric antigen receptor T cell infusions for patients with positive CD19, BCMA relapse or refractory multiple myeloma
Latest Information Update: 05 Feb 2020
At a glance
- Drugs Anti-CD19-anti-BCMA-CAR-T-cell-therapy-Suzhou Maximum Bio-tech (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
Most Recent Events
- 05 Feb 2020 New trial record